Generic launches don’t “just happen.” They’re engineered by time, law, and leverage.
If you’re still forecasting generic drug launch dates using spreadsheets and historical averages, you’re already behind. In today’s patent landscape—where exclusivit…

Most people “mine” the FDA Orange Book for patents. The real edge is mining it for people.
If you’re sourcing BD leads, scouting licensing targets, or building a pipeline of potential partners, you already know the Orange Book is a goldmine of assets. …

Biotech investors love “pipeline value,” but most portfolios are still ranked like spreadsheets—without a disciplined way to translate timing and risk into profitability.
That’s where NPV and the Profitability Index (PI) stop being academic finance ter…

The “Patent Cliff” Isn’t Just a Pharma Problem—It’s a Talent Problem.
If you think the next wave of biopharma disruption will be driven only by pipeline failures and blockbuster expirations, you’re missing a quieter—and faster—shift happening in the la…

Stop Overstocking: How Patent Intelligence Helps Wholesalers Cut Branded Drug Inventory Risk
Overstocking branded drugs isn’t just a balance-sheet problem—it’s a timing problem.
In branded pharmaceuticals, the clock is always running: patent expiration…

Big Pharma doesn’t just “feel” a patent cliff—it signals it.
If you want to understand workforce shifts before they show up in earnings calls, headcount dashboards, or press releases, look at the events that happen around patent cliffs. Not the headlin…

Biosimilars are no longer a “someday” play. They’re a sourcing strategy.
If you’re still treating biosimilar switching as a procurement afterthought, you’re likely paying the price twice: first in missed timing, then in avoidable supply and contracting…

Pharma has a familiar playbook: take an old molecule, repackage it as “new,” and price it like it’s never been seen before.
That’s the tension at the heart of the latest discussion from DrugPatentWatch—how companies justify premium pricing for repurpos…

Pharma hiring is broken—at least when it comes to how we find “the best scientists.”
Most recruiters still treat talent like a spreadsheet: search titles, scan keywords, match therapeutic areas, move on. But in life sciences, where innovation is cumula…

Pharma has a new way to sell “innovation” without inventing much: repackage old drugs, re-label them for new indications, and justify premium pricing as if the science were brand-new.
That’s the core tension highlighted in a recent DrugPatentWatch piec…